Search Results
Dec 12, 2025, 09:03 ET Top Crunch Fitness Franchisee Brings First-Ever HVLP Reformer Pilates Studio to McKinney, Texas
with plans to expand into Arizona.About CR Fitness Holdings, LLCCR Fitness Holdings, LLC is the leading franchisee of Crunch Fitness, and led by a management team with over 150 years of combined experience in the fitness industry. CR Fitness is on track to operate 100 locations nationwide
More news about: CR Fitness Holdings, LLC.
Dec 12, 2025, 08:45 ET Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition,
More news about: Actinium Pharmaceuticals, Inc.
Dec 12, 2025, 00:38 ET TELUS Announces Upsizing and Results of its Cash Tender Offers for Seven Series of Debt Securities
-4.75% Notes,Series CR dueJanuary, 2045C$400,000,000
More news about: TELUS Corporation
Dec 12, 2025, 00:38 ET TELUS Announces Upsizing and Results of its Cash Tender Offers for Seven Series of Debt Securities
-4.75% Notes,Series CR dueJanuary, 2045C$400,000,000
More news about: TELUS Corporation
Dec 11, 2025, 12:30 ET TalkShopLive Appoints Former TikTok Ecommerce Leader Sandie Hawkins as CEO Amid Strategic Expansion
https://www.dropbox.com/scl/fi/cr6zlcynnk2d7yfn5146x/Sandie-Hawkins.jpg?rlkey=iqm15cvn0qz9qkxfp947hy5pr&st=8sjec5jp&dl=0LOS ANGELES, Dec.
More news about: talkshoplive
Dec 11, 2025, 10:01 ET SK Chemicals effectue la première intégration verticale du recyclage en Corée grâce à un approvisionnement interne en matières premières
recyclage chimique à Shantou en Chine, créant ainsi un centre mondial pour le recyclage circulaire avec la production commerciale de r-BHET et de CR-PET. En Corée, l'entreprise a construit le centre d'innovation du recyclage (Recycle Innovation Center - RIC) dans son usine d'Ulsan, reliant les installations
More news about: SK Chemicals
Dec 11, 2025, 09:25 ET SK Chemicals realisiert durch die hausinterne Beschaffung von Rohstoffen die erste vertikale Integration im Recyclingbereich in Korea
chemisches Recycling in Shantou, China, und schuf damit einen globalen Hub für zirkuläres Recycling mit der kommerziellen Produktion von r-BHET und CR-PET. In Korea hat das Unternehmen in seinem Werk in Ulsan das Recycle Innovation Center (RIC) errichtet, das Pilotanlagen zur Depolymerisation mit der Copolyester-Produktion
More news about: SK Chemicals
Dec 11, 2025, 08:30 ET Market For Geologic Hydrogen & Carbon Capture Is Burgeoning, With Revenues Projected to Hit Over $50 Billion
a mineralized zone exceeding 700 metres strike length, individual lenses up to 45 metres long by 10 metres wide, and microprobe grades up to 60.45% Cr₂O₃."Natural accumulations of geologic hydrogen are being found all over the world, but in most cases they are small and not economical, although
More news about: FN Media Group, LLC
Dec 11, 2025, 07:30 ET TuHURA Biosciences Provides Corporate Update Following Recent Financing
while menin inhibitors have become standard of care in NPM1 mutated AML, there still exists a significant unmet medical need, citing the relatively low CR rate and short duration of response as the two obstacles to improving clinical benefit in these patients."Dr. Bianco continued, "The VISTA gene
More news about: TuHURA Biosciences, Inc.
Dec 11, 2025, 07:22 ET Citius TransNet Investment Trust Files Draft Offer Document with SEBI for Rs 1,340 Cr InvIT
content:https://www.prnewswire.com/in/news-releases/citius-transnet-investment-trust-files-draft-offer-document-with-sebi-for-rs-1-340-cr-invit-302639103.html
More news about: Citius TransNet Investment Trust
Dec 10, 2025, 18:34 ET SK Chemicals logra la primera integración vertical de Corea en reciclaje
producción basada en el reciclaje químico en Shantou (China), creando un centro global para el reciclaje circular con la producción comercial de r-BHET y CR-PET. En Corea, la empresa ha construido el Centro de Innovación en Reciclaje (RIC) en su planta de Ulsan, conectando las instalaciones piloto de despolimerización
More news about: SK Chemicals
Dec 10, 2025, 08:30 ET IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
mm), followed by Cryoablation-only (61.7%, mean reduction of 8.2 mm), and HT-only (42.1%, mean reduction of 7.4 mm). Tumors with complete remission (CR, RECIST 1.1) were similar between the Cryoablation-with-HT and Cryoablation-only groups (74.4% and 78.3%, respectively), followed by the HT-only (36.1%).
More news about: IceCure Medical
Dec 10, 2025, 08:00 ET SK Chemicals achieves Korea's first vertical integration in recycling through in-house feedstock sourcing
recycling-based production subsidiary in Shantou, China, in 2023, creating a global hub for circular recycling with the commercial production of r-BHET and CR-PET. In Korea, the company has built the Recycle Innovation Center (RIC) at its Ulsan plant, linking depolymerization pilot facilities with copolyester
More news about: SK Chemicals
Dec 10, 2025, 02:00 ET SK Chemicals achieves Korea's first vertical integration in recycling through in-house feedstock sourcing
recycling-based production subsidiary in Shantou, China, in 2023, creating a global hub for circular recycling with the commercial production of r-BHET and CR-PET. In Korea, the company has built the Recycle Innovation Center (RIC) at its Ulsan plant, linking depolymerization pilot facilities with copolyester
More news about: SK Chemicals
Dec 09, 2025, 08:00 ET Curis Provides Updated Data from its Frontline AML Triplet Study
to the combination with venetoclax and azacitidine (ema-ven-aza) in AML patients being treated with ven-aza in the frontline setting who have achieved CR but remain MRD-positive. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML
More news about: Curis, Inc.
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
combination across varied patient measures.1 TECVAYLI® plus DARZALEX FASPRO® showed higher rates of complete response (≥CR) (81.8% vs. 32.1%; odds ratio [OR], 9.56; 95% CI, 6.47-14.14), overall response (89.0% vs. 75.3%; OR, 2.65; 95% CI, 1.68-4.18) and MRD-negativity (58.4%
More news about: Johnson & Johnson
Dec 09, 2025, 05:00 ET Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
maintenance after CHOP, showed an ORR of 94.1% and a CR rate of 64.7%. By the data cutoff date, 85% of patients remained on treatment.Golidocitinib 150mg daily with CHOP, followed by 150mg maintenance after CHOP, showed an ORR of 88.9% and a CR rate of 61.1% R/R
More news about: Dizal Pharmaceutical
Dec 09, 2025, 02:47 ET Innoviti Appoints Sandeep Mina As Chief Business Officer - Retail
payments-centric SaaS software is used by enterprise brands and their SME channel partners across online and offline payment channels, processing over Rs. 80,000 Cr. annually from across 2000 cities and over 20,000 merchants. The company processes more than 50% of all purchases happening in enterprise retailers in
More news about: Innoviti Technologies Pvt. Ltd.
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
received a prior menin inhibitor. In the NPM1m dose optimization population (n=25, pts who received ≥ 200 mg BID), ORR is 52% and CR+CR is 44% with a duration of CR+CRh of 5.7 months. The mOS was 8.5 months."Despite improved understanding of the genetic factors of certain high-risk subtypes
More news about: Sumitomo Pharma America
Dec 08, 2025, 10:30 ET Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition
azacitidine, and the result for that endpoint was 0.913 (90% confidence interval [CI]: 0.78, 1.07).In patients with MDS (n=22), the complete response (CR) rate was 22.7% and overall response rate was 50%.Among patients who were dependent on red blood cell (RBC) transfusions at baseline (n=13),
More news about: Taiho Oncology
Dec 08, 2025, 08:31 ET QuesTek Wins First Place in AM Bench 2025 Challenge for Predicting Phase Transformations in Fe-Cr-Ni Alloys
qualification."About the ChallengeThe challenge focused on predicting the sequence of phases that form during rapid solidification in Fe-Cr-Ni alloys with different Cr/Ni ratios. These alloys serve as a model system for many stainless steels, and are particularly relevant to AM because the process involves
More news about: QuesTek Innovations
Dec 07, 2025, 21:08 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
months (range: 0.9-7.9 months). Six patients achieved a partial response (PR) or better: 3 achieved complete response/stringent complete response (CR/sCR) (all in the full-dose lymphodepletion group), 1 achieved very good partial response (VGPR), and 2 achieved PR. Among the 6 patients who received full-dose
More news about: CARsgen Therapeutics
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
efficacy across dose levels 400–1200 μg/kg (n=40).ORR reached 82.5%, with ≥CR at 52.5%, ≥VGPR at 72.5%, and MRD negativity at 80.0%.At 800 μg/kg, ORR and ≥CR were 90.9% and 63.6%, respectively.Robust activity in difficult-to-treat RRMM
More news about: Leads Biolabs
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
10 patients with EMD and 77.8% in 9 patients who had previously received anti-BCMA and/or anti-GPRC5D therapies.Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing (NGS) testing, the minimal residual disease (MRD) negativity rate was 100% (n=4).Potent
More news about: Innovent Biologics
Dec 07, 2025, 19:15 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
months (range: 0.9-7.9 months). Six patients achieved a partial response (PR) or better: 3 achieved complete response/stringent complete response (CR/sCR) (all in the full-dose lymphodepletion group), 1 achieved very good partial response (VGPR), and 2 achieved PR. Among the 6 patients who received full-dose
More news about: CARsgen Therapeutics